Using Optical Coherence Tomography to Diagnose Oral Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Optical Coherence Tomography (OCT) for the early diagnosis of oral cancer, particularly focusing on Oral Potentially Malignant Disorders (OPMDs) that can lead to Oral Squamous Cell Carcinoma (OSCC). The study compares OCT imaging with traditional histology, aiming to create a database of OCT data to enhance non-invasive identification of cancerous changes in oral tissues. By providing detailed cross-sectional images, OCT may improve the accuracy and efficiency of diagnosing early-stage oral lesions, potentially reducing the need for invasive biopsies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult patients with clinical suspicion of potentially malignant oral disorders (OPMDs) and oral squamous cell carcinoma (OSCC).
2. Patients able to provide informed consent for participation in the study.
3. Availability of complete clinical data and medical records.

Exclusion Criteria:

1. Patients with a previous diagnosis of OSCC/OPMDs and/or who have already undergone treatment.
2. Patients with contraindications to the OCT examination for nonpermissive oral localization using the probe.
3. Pregnant or breastfeeding women.
4. Patients with disabilities, reluctance or difficulties of understanding to follow the procedures of the study and who have not provided a consent.

Where it's running

• University of Palermo
  Palermo, Italy Recruiting

Study contacts

• Principal investigator: Vera Panzarella — University of Palermo
• Study coordinator: Vera Panzarella
• Email: vera.panzarella@unipa.it
• Phone: 091 6554612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Salivary IL-8 and Serum IL-6 as Biomarkers to Distinguish Oral Premalignant Disorders in Smokers and Never-Smokers

  This study tests whether salivary IL-8 and blood IL-6 can help tell apart adults with oral premalignant conditions from those with healthy mouths, and whether smoking influences these markers.

  Recruiting British University In Egypt · Cairo · NCT07915570

• Pre-surgery metronidazole and chlorhexidine to lower bacteria in oral cavity tumors

  This study will try a short course of the antibiotic metronidazole plus chlorhexidine mouthwash before surgery to see if it lowers bacteria inside tumors in adults with oral squamous cell carcinoma.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06627270

• Using Ruxolitinib to prevent complications after haploidentical stem cell transplants

  This study is testing if the drug Ruxolitinib can help prevent complications like graft-versus-host disease in patients receiving stem cell transplants from partially matched donors.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06008808

• Predicting cancer risk in oral leukoplakia using MAGE-A markers

  This study is trying to see if certain markers in people with oral leukoplakia can help predict their risk of developing oral cancer.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen · NCT03975322

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.